887244-16-8Relevant articles and documents
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy
Thomson, Stephen A.,Banker, Pierette,Bickett, D. Mark,Boucheron, Joyce A.,Carter, H. Luke,Clancy, Daphne C.,Cooper, Joel P.,Dickerson, Scott H.,Garrido, Dulce M.,Nolte, Robert T.,Peat, Andrew J.,Sheckler, Lauren R.,Sparks, Steven M.,Tavares, Francis X.,Wang, Liping,Wang, Tony Y.,Weiel, James E.
scheme or table, p. 1177 - 1182 (2009/09/04)
Key binding interactions of the anthranilimide based glycogen phosphorylase a (GPa) inhibitor 2 from X-ray crystallography studies are described. This series of compounds bind to the AMP site of GP. Using the binding information the core and the phenyl ur
